Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sacituzumab Tirumotecan”

61 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 61 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07438626
What this trial is testing

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Who this might be right for
Phase IISacituzumabTirumotecan+1 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Large-scale testing (Phase 3)Active Not RecruitingNCT06356311
What this trial is testing

Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Who this might be right for
Gastroesophageal Cancer
Merck Sharp & Dohme LLC 450
Large-scale testing (Phase 3)Not Yet RecruitingNCT07628504
What this trial is testing

Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

Who this might be right for
Adjuvant Drug Therapy
Fudan University 420
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07348861
What this trial is testing

A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Who this might be right for
Cervical Cancer
Zheng Min 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244926
What this trial is testing

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 31
Testing effectiveness (Phase 2)Looking for participantsNCT07256236
What this trial is testing

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
Fujian Cancer Hospital 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Large-scale testing (Phase 3)Looking for participantsNCT07419295
What this trial is testing

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 590
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT06637423
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07007780
What this trial is testing

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

Who this might be right for
Triple -Negative Breast Cancer
Xijing Hospital 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07511023
What this trial is testing

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

Who this might be right for
Phase 2Sacituzumab TirumotecanRefractory Metastatic+2 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07388875
What this trial is testing

Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC

Who this might be right for
Extensive-Stage Small Cell Lung Cancer
China Medical University, China 30
Large-scale testing (Phase 3)Looking for participantsNCT07216703
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 1,023
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284
What this trial is testing

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Who this might be right for
ER+HER2- Breast Cancer
West China Hospital 55
Large-scale testing (Phase 3)Looking for participantsNCT06422143
What this trial is testing

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Who this might be right for
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC 851
Large-scale testing (Phase 3)Looking for participantsNCT06824467
What this trial is testing

Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Merck Sharp & Dohme LLC 770
Testing effectiveness (Phase 2)Looking for participantsNCT07548060
What this trial is testing

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07521670
What this trial is testing

Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)

Who this might be right for
Recurrent Adenoid Cystic CarcinomaAdenoid Cystic Carcinoma MetastaticPapillary Thyroid Carcinoma
National Cancer Centre, Singapore 68
Load More Results